



CONTENTS

Minireview

- 613 **Proteases as Prognostic Markers in Cancer.** M. J. Duffy.

Advances in Brief

- 619 **Treatment of Recurrent Malignant Gliomas with Chronic Oral High-Dose Tamoxifen.** William T. Couldwell, David R. Hinton, Amy A. Surnock, Christopher M. DeGiorgio, Leslie P. Weiner, Michael L. J. Apuzzo, Lena Masri, Ronald E. Law, and Martin H. Weiss.
- 623 **Apoptotic Death of Tumor Cells Correlates with Chemosensitivity, Independent of p53 or Bcl-2.** Gen Sheng Wu and Wafik S. El-Deiry.

Research Articles

- 635 **Reduced Levels of Transforming Growth Factor β Receptor Type II in Human Prostate Cancer: An Immunohistochemical Study.** Russel H. Williams, Alan M. F. Stapleton, Guang Yang, Luan D. Truong, Eammon Rogers, Terry L. Timme, Thomas M. Wheeler, Peter T. Scardino, and Timothy C. Thompson.
- 641 **Tumor Escape from Immune Recognition: Loss of HLA-A2 Melanoma Cell Surface Expression Is Associated with a Complex Rearrangement of the Short Arm of Chromosome 6.** Markus J. Maeurer, Susanne M. Gollin, Walter J. Storkus, William Swaney, Julia Karbach, Dina Martin, Chiara Castelli, Russell Salter, Alex Knuth, and Michael T. Lotze.
- 653 **Influence of Fludarabine on Pharmacokinetics and Pharmacodynamics of Cytarabine: Implications for a Continuous Infusion Schedule.** John F. Seymour, Peng Huang, William Plunkett, and Varsha Gandhi.
- 659 **Phase I Clinical Trial of the Flavonoid Quercetin: Pharmacokinetics and Evidence for *in Vivo* Tyrosine Kinase Inhibition.** David R. Ferry, Anna Smith, Joy Malkhandi, David W. Fyfe, Philippa G. deTakats, David Anderson, Jim Baker, and David J. Kerr.
- 669 **Daily Subcutaneous Injection of Low-Dose Interleukin 2 Expands Natural Killer Cells *in Vivo* without Significant Toxicity.** Neal J. Meropol, Michelle Porter, Leslie E. Blumenson, Matthew J. Lindemann, Raymond P. Perez, Louis Vaickus, Gregory M. Loewen, Patrick J. Creaven, Kimberly A. Wilkes, Martin A. Giedlin, and Michael A. Caligiuri.
- 679 **Immunization of Melanoma Patients with BEC2 Anti-idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside: Enhanced Immunogenicity When Combined with Adjuvant.** Mary McCaffery, Tzy-Jyun Yao, Linda Williams, Philip O. Livingston, Alan N. Houghton, and Paul B. Chapman.
- 687 **Potential of Cisplatin Cytotoxicity by 9-Aminocamptothecin.** François Goldwasser, Monica Valenti, Rosimar Torres, Kurt W. Kohn, and Yves Pommier.
- 695 **Establishment and Serial Quantification of Intrahepatic Xenografts of Human Hepatocellular Carcinoma in Severe Combined Immunodeficiency Mice, and Development of Therapeutic Strategies to Overcome Multidrug Resistance.** Cynthia R. Leveille-Webster and Irwin A. Arias.
- 707 **Polyglutamylation of the Dihydrofolate Reductase Inhibitor γ -Methylene-10-deazaaminopterin Is Not Essential for Antitumor Activity.** S. Cao, A. Abraham, M. G. Nair, R. Pati, J. H. Galivan, F. H. Hausheer, and Y. M. Rustum.
- 713 **Cyclosporin A and PSC 833 Prevent Up-Regulation of MDR1 Expression by Anthracyclines in a Human Multidrug-resistant Cell Line.** Xiu F. Hu, Alison Slater, Dominic M. Wall, John D. Parkin, Phillip Kantharidis, and John R. Zalberg.
- 721 **Aerosol Delivery of Interleukin 2 Liposomes Is Nontoxic and Biologically Effective: Canine Studies.** Chand Khanna, Diane E. Hasz, Jeffrey S. Klausner, and Peter M. Anderson.
- 735 **Role of *O*⁶-Methylguanine-DNA Methyltransferase in Resistance of Human Brain Tumor Cell Lines to the Clinically Relevant Methylating Agents Temozolomide and Streptozotocin.** Michael S. Bobola, Sheng Hong Tseng, A. Blank, Mitchel S. Berger, and John R. Silber.
- 743 **Clonal Analysis of Bilateral Breast Cancer.** Atsuko Shibata, Yvonne C. Tsai, Michael F. Press, Brian E. Henderson, Peter A. Jones, and Ronald K. Ross.
- 749 **Establishment of a Quantitative Assay of Abnormal Glycolipid Expression in Endometrial Cells, and Its Diagnostic Value for Endometrial Carcinoma.** Yoichi Kobayashi, Katsumi Tsukazaki, Kaneyuki Kubushiro, Motoko Sakayori, and Shiro Nozawa.
- 755 **Human Papilloma Virus and p53 in Head and Neck Cancer: Clinical Correlates and Survival.** Daniel J. Haraf, Edwardine Nodzinski, David Brachman, Rosemarie Mick, Anthony Montag, Deborah Graves, Everett E. Vokes, and Ralph R. Weichselbaum.
- 763 **Prognostic Value and Clinicopathological Correlation of Thrombomodulin in Squamous Cell Carcinoma of the Human Lung.** Motoharu Hamatake, Teruyoshi Ishida, Tetsuya Mitsudomi, Kouhei Akazawa, and Keizo Sugimachi.
- 767 **T-Cell Receptor β Variable Region Diversity in Melanoma Metastases after Interleukin 2-based Immunotherapy.** Martina Willhauck, Thomas Möhler, Carmen Scheibenbogen, Michael Pawlita, Peter Brossart, Johann W. Schmier, and Ulrich Keilholz.
- 773 **Localization of Platelet-derived Growth Factor β Receptor Expression in the Periepithelial Stroma of Human Breast Carcinoma.** Bhavna Bhardwaj, Jennifer Klassen, Nadine Cossette, Ernest Sterns, Alan Tuck, Roger Deeley, Sandip Sengupta, and Bruce Elliott.
- 783 **AACR Bulletin Board**
Annual Meeting
Workshop on Methods in Clinical Cancer Research
AACR Special Conferences in Cancer Research

i Instructions for Authors

This One



Clinical Cancer Research

2 (4)

Clin Cancer Res 1996;2:613-782.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/2/4.citation>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/2/4.citation>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.